Major pharmaceutical shift underway. Amgen and GSK have joined President Trump's TrumpRx.gov initiative, bringing the total to 54 prescription medications from six companies offering significant discounts through most-favored-nation pricing. Amgen's Amjevita, used for rheumatoid arthritis and psoriasis, will be discounted 80 percent, dropping from $1,484 to $299. The company also plans 62 percent discounts on Aimovig and Repatha. GSK will offer Incruse at 55 percent off retail price for COPD treatment, listed at $159, with additional medications discounted between 10 and 51 percent. The White House framed this as a milestone in affordability efforts, though industry representatives warn that government-imposed pricing policies could undermine research and development competitiveness in the United States.
